U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Atomoxetine (marketed as Strattera) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Atomoxetine (marketed as Strattera) Information

Atomoxine (marketed as Strattera) is currently approved in the United States to treat attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. 


This information reflects FDA’s current analysis of data available to FDA concerning this drug. FDA intends to update this page when additional information or analyses become available 


Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this page.

 

Related Information

Labeling and Regulatory History from Drugs@FDA